Search results for "HEPATOCELLULAR-CARCINOMA"

showing 9 items of 9 documents

The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria–In Patients Waiting for Liver Transplantation

2019

In patients with hepatocellular carcinoma (HCC) meeting the Milan criteria (MC), the benefit of locoregional therapies (LRTs) in the context of liver transplantation (LT) is still debated. Initial biases in the selection between treated and untreated patients have yielded conflicting reported results. The study aimed to identify, using a competing risk analysis, risk factors for HCC-dependent LT failure, defined as pretransplant tumor-related delisting or posttransplant recurrence. The study was registered at www.clinicaltrials.gov (identification number NCT03723304). In order to offset the initial limitations of the investigated population, an inverse probability of treatment weighting (IP…

Ablation TechniquesGraft RejectionMaleTime FactorsHepatocellular carcinomaIMPACTmedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEintent to treatLOCOREGIONAL THERAPYKaplan-Meier Estimate030230 surgeryLiver transplantationLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCOREGastroenterologyLiver disease0302 clinical medicineRisk FactorsHEPATOCELLULAR-CARCINOMAHepatocellular carcinoma liver transplantation risk factors intent to treat prognostic score waiting listeducation.field_of_studyLiver NeoplasmsAge FactorsDEATHwaiting listMiddle AgedCANCERprognostic scoreIntention to Treat AnalysisTIMETreatment OutcomeHepatocellular carcinomaDisease ProgressionSURVIVAL030211 gastroenterology & hepatologyFemalemedicine.symptommedicine.medical_specialtyCarcinoma HepatocellularWaiting ListsALPHA-FETOPROTEINPopulationMilan criteriamRECISTRisk AssessmentLesionalpha-fetoprotein03 medical and health sciencesSex FactorsInternal medicinePreoperative CaremedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapieseducationRECURRENCEOUTCOMETransplantationLiver transplantationIntention-to-treat analysisHepatologybusiness.industryHEPATOCELLULAR-CARCINOMA; ALPHA-FETOPROTEIN; LOCOREGIONAL THERAPY; RECURRENCE; CANCER; MODEL; TIME; SURVIVAL; IMPACT; DEATHlocoregional therapymedicine.diseaseSettore MED/18Liver TransplantationMODELhepatocellular cancerTumor progressionSurgerybusinessFollow-Up Studies
researchProduct

Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection

2002

Abstract OBJECTIVES: The virological profiles of hepatitis B and C viruses (HBV and HCV) and their interplay in cases of coinfection are undefined. A suppressed and occult HBV infection may occur in hepatitis B surface antigen (HBsAg) negative patients with chronic hepatitis C. The HCV core protein is able to inhibit HBV “in vitro,” and serines at positions 99 and 116 are essential for such inhibition. We aimed to assess the HBV and HCV virological profiles in cases of coinfection and to evaluate the relationship between HCV core gene variability and HBV activity. METHODS: Eighty-two anti-HCV positive patients were examined: 35 cases were HBsAg positive, 24 were HBsAg negative with “occult”…

AdultMaleHepatitis B virusHBsAgHCV RNAHepacivirusHepatitis C virusDUAL INFECTION; INTERFERON THERAPY; HEPATOCELLULAR-CARCINOMA; CHRONIC LIVER-DISEASE; HCV core protein; Hepatitis B Surface Antigens; HCV RNAGenome ViralHepacivirusDUAL INFECTIONVirus Replicationmedicine.disease_causeCHRONIC LIVER-DISEASEHepatitis B ChronicINTERFERON THERAPYOrthohepadnavirusHEPATOCELLULAR-CARCINOMAmedicineHumansAgedHepatitis B virusHepatitis B Surface AntigensHepatologybiologybusiness.industryHCV core proteinGastroenterologyvirus diseasesHepatitis C ChronicMiddle AgedViral LoadHepatitis Bbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesHepadnaviridaeDNA ViralImmunologyCoinfectionRNA ViralFemalebusinessThe American Journal of Gastroenterology
researchProduct

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

2004

Background: The key end point for treatment efficacy in chronic hepatitis C is absence of detectable virus at six months after treatment. However, the incidence of clinical events during long term follow up of patients with sustained virological response is still poorly documented and may differ between the Eastern and Western world. Aims: To assess clinical end points during long term follow up of European patients with a sustained virological response to interferon monotherapy. Methods: Meta-analysis of individual patient data from eight European protocolled follow up studies of interferon treatment for chronic hepatitis C. Results: A total of 286 sustained virological responders and 50 b…

AdultMalemedicine.medical_specialtyPlus ribavirinCirrhosisHepatocellular-CarcinomaAdolescentFibrosiPopulationAlpha interferonAntiviral AgentsSDG 3 - Good Health and Well-beingInternal medicinemedicineHumansDecompensationeducationSurvival analysisAgededucation.field_of_studyCirrhosibusiness.industryIncidence (epidemiology)Follow-upNatural-historyGastroenterologyCohortHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseSurvival AnalysisImpactTreatment OutcomeLiverHepatocellular carcinomaImmunologyRegression AnalysisFemaleTherapyInterferonsbusinessAlpha-interferonGut
researchProduct

Recent advances in smart biotechnology: Hydrogels and nanocarriers for tailored bioactive molecules depot

2017

Over the past ten years, the global biopharmaceutical market has remarkably grown, with ten over the top twenty worldwide high performance medical treatment sales being biologics. Thus, biotech R&D (research and development) sector is becoming a key leading branch, with expanding revenues. Biotechnology offers considerable advantages compared to traditional therapeutic approaches, such as reducing side effects, specific treatments, higher patient compliance and therefore more effective treatments leading to lower healthcare costs. Within this sector, smart nanotechnology and colloidal self-assembling systems represent pivotal tools able to modulate the delivery of therapeutics. A comprehens…

Bioactive molecules02 engineering and technologyHepatocellular-carcinoma cells01 natural sciencesMiceColloid and Surface ChemistryDrug Delivery SystemsCarbon nano materialNanotechnologyMolecular Targeted TherapyTransgenesRNA Small InterferingPatient complianceTransfer radical polymerizationMicro/nanocarrierMedical treatmentMicro/nanocarriersBioactive molecule deliveryHydrogelsSurfaces and Interfaces021001 nanoscience & nanotechnologyLiposomeBiopharmaceuticalOral deliverySelf-healing hydrogelsIntercellular Signaling Peptides and Proteins0210 nano-technologyAssembling peptide hydrogelsSurfaces and InterfaceNucleic-acid deliveryPlasmidsDiagnostic ImagingSolid lipid nanoparticlesNanotechnology010402 general chemistryAntibodiesSmall Molecule LibrariesCarbon nano-onionsIn-vivoAnimalsHumansPhysical and Theoretical Chemistrybusiness.industryDrug-delivery0104 chemical sciencesBiotechnologyHydrogelSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoMolecular ProbesBioactive molecule delivery; Carbon nano materials; Hydrogels; Liposomes; Micro/nanocarriers; Surfaces and Interfaces; Physical and Theoretical Chemistry; Colloid and Surface ChemistryLiposomesNonviral gene deliveryCarbon nano materialsNanoparticlesBusinessNanocarriers
researchProduct

Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial

2012

    In a prospective, multicenter, open-label study, de novo liver transplant patients were randomized at day 30±5 to (i) everolimus initiation with tacrolimus elimination (TAC Elimination) (ii) everolimus initiation with reduced-exposure tacrolimus (EVR+Reduced TAC) or (iii) standard-exposure tacrolimus (TAC Control). Randomization to TAC Elimination was terminated prematurely due to a higher rate of treated biopsy-proven acute rejection (tBPAR). EVR+Reduced TAC was noninferior to TAC Control for the primary efficacy endpoint (tBPAR, graft loss or death at 12 months posttransplantation): 6.7% versus 9.7% (-3.0%; 95% CI -8.7, 2.6%; p<0.001 for noninferiority [12% margin]). tBPAR occurred in…

Graft RejectionCHRONIC KIDNEY-DISEASEMaleTime Factorsmedicine.medical_treatmentMedizinKaplan-Meier EstimateLiver transplantationKidneyKidney Function TestsGLOMERULAR-FILTRATION-RATEImmunosuppressive AgentHEPATOCELLULAR-CARCINOMASIROLIMUS-BASED IMMUNOSUPPRESSIONImmunology and AllergySirolimuPharmacology (medical)Prospective StudiestacrolimusMYCOPHENOLATE-MOFETILCOMPLICATIONSCross-Over Studiesliver transplantationwithdrawalGraft SurvivalCross-Over StudieMiddle AgedTreatment Outcomesurgical procedures operativeSurvival AnalysireducedLife Sciences & BiomedicineImmunosuppressive AgentsHumanGlomerular Filtration Ratemedicine.drugAdultmedicine.medical_specialtyRandomizationTime FactorAdolescentEfficacyUrologyRenal functionchemical and pharmacologic phenomenaCALCINEURIN INHIBITORRisk AssessmentDrug Administration ScheduleFollow-Up StudieYoung Adultstomatognathic systemTransplantation ImmunologyDOSE TACROLIMUSConfidence IntervalsmedicineHumansMETAANALYSISAgedSirolimusTransplantationKidney Function TestScience & TechnologyEverolimusDose-Response Relationship Drugbusiness.industryeverolimutacrolimuOriginal ArticleseverolimusSurvival AnalysisCrossover studyTacrolimusSurgeryTransplantationProspective StudieCONVERSIONstomatognathic diseasesSirolimusSurgerybusinessConfidence IntervalLiver FailureFollow-Up StudiesAmerican Journal of Transplantation
researchProduct

Genome-Wide Association Analysis in Primary Sclerosing Cholangitis

2010

Background & Aims We aimed to characterize the genetic susceptibility to primary sclerosing cholangitis (PSC) by means of a genome-wide association analysis of single nucleotide polymorphism (SNP) markers. Methods A total of 443,816 SNPs on the Affymetrix SNP Array 5.0 (Affymetrix, Santa Clara, CA) were genotyped in 285 Norwegian PSC patients and 298 healthy controls. Associations detected in this discovery panel were re-examined in independent case-control panels from Scandinavia (137 PSC cases and 368 controls), Belgium/The Netherlands (229 PSC cases and 735 controls), and Germany (400 cases and 1832 controls). Results The strongest associations were detected near HLA-B at chromosome 6p21…

LOCIMacrophage Stimulating 1 (Hepatocyte Growth Factor-Like)Genome-wide association studySUSCEPTIBILITYGene FrequencyHLA AntigensRisk FactorsHEPATOCELLULAR-CARCINOMAOdds RatioBileBiliary TractINCREASED RISKOligonucleotide Array Sequence AnalysisGastroenterologyMULTIPLE-SCLEROSISCROHNS-DISEASEEuropePhenotypeULCERATIVE-COLITISInflammation MediatorsSNP arrayCholangitis SclerosingSingle-nucleotide polymorphismLocus (genetics)Human leukocyte antigenBiologyPolymorphism Single NucleotideRisk AssessmentCell LinePrimary sclerosing cholangitisGlypicansGenetic predispositionmedicineHumansGenetic Predisposition to DiseaseGene SilencingACID RECEPTOR TGR5Genetic associationInflammationChi-Square DistributionHepatologyGene Expression ProfilingGlypican 6medicine.diseaseGENEG-Protein-Coupled Bile Acid Receptor 1Case-Control StudiesImmunologyColitis UlcerativeGenome-Wide Association StudyINFLAMMATORY-BOWEL-DISEASEGastroenterology
researchProduct

Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel.

2010

AbstractChelation therapy with new drugs prevents cardiac damage and improves the survival of thalassemia patients. Liver diseases have emerged as a critical clinical issue. Chronic liver diseases play an important role in the prognosis of thalassemia patients because of the high frequency of viral infections and important role of the liver in regulating iron metabolism. Accurate assessment of liver iron overload is required to tailor iron chelation therapy. The diagnosis of hepatitis B virus– or hepatitis C virus–related chronic hepatitis is required to detect patients who have a high risk of developing liver complications and who may benefit by antiviral therapy. Moreover, clinical manage…

Liver Cirrhosisthalassemiamedicine.medical_specialtyCirrhosisC VIRUS-INFECTION; HOMOZYGOUS BETA-THALASSEMIA; TRANSFUSION-DEPENDENT THALASSEMIA; TERM-FOLLOW-UP; IRON OVERLOAD; LIVER-DISEASE; INTERFERON-ALPHA; RISK-FACTORS; INTRAFAMILIAL TRANSMISSION; HEPATOCELLULAR-CARCINOMAHepatitis C virusThalassemiaImmunologymedicine.disease_causeChronic liver diseaseAntiviral AgentsBiochemistryHOMOZYGOUS BETA-THALASSEMIALiver diseaseHepatitis B ChronicLIVER-DISEASEHEPATOCELLULAR-CARCINOMAmedicineTRANSFUSION-DEPENDENT THALASSEMIAIRON OVERLOADHumansIntensive care medicineTERM-FOLLOW-UPchronic viral hepatitis; thalassemia; managementbusiness.industryCell BiologyHematologyHepatitis CHepatitis C ChronicHepatitis Bmedicine.diseaseINTRAFAMILIAL TRANSMISSIONchronic viral hepatitisImmunologyRISK-FACTORSINTERFERON-ALPHAViral hepatitisbusinessC VIRUS-INFECTIONmanagement
researchProduct

The Southampton Consensus Guidelines for Laparoscopic Liver Surgery: From Indication to Implementation

2018

OBJECTIVE: The European Guidelines Meeting on Laparoscopic Liver Surgery was held in Southampton on February 10 and 11, 2017 with the aim of presenting and validating clinical practice guidelines for laparoscopic liver surgery.BACKGROUND: The exponential growth of laparoscopic liver surgery in recent years mandates the development of clinical practice guidelines to direct the speciality's continued safe progression and dissemination.METHODS: A unique approach to the development of clinical guidelines was adopted. Three well-validated methods were integrated: the Scottish Intercollegiate Guidelines Network methodology for the assessment of evidence and development of guideline statements; th…

Liver surgerymedicine.medical_specialtyDelphi TechniqueColorectal cancerindicationMEDLINE030230 surgeryCENTRAL VENOUS-PRESSUREINITIAL-EXPERIENCECOLORECTAL-CANCER03 medical and health sciences0302 clinical medicineSouthamptonOPEN LEFT HEMIHEPATECTOMYHEPATOCELLULAR-CARCINOMAmedicineHepatectomyHumansguidelinesproceduresimplementationPOSTEROSUPERIOR SEGMENTSbusiness.industryLiver DiseasesENERGY DEVICElaparoscopic liver surgerytechniquemedicine.disease2-STAGE HEPATECTOMYEnergy deviceclinical practiceSurgeryEuropeClinical PracticeGLISSONIAN APPROACHconsensus030220 oncology & carcinogenesisHepatocellular carcinomaLaparoscopySurgeryLEARNING-CURVEbusinesspatient selectionAnnals of surgery
researchProduct

Occult hepatitis B virus infection

2000

Many studies have shown that hepatitis B virus infection may also occur in hepatitis B surface antigen-negative patients. This occult infection has been identified both in patients with cryptogenic liver disease and in patients with hepatitis C virus-related chronic hepatitis, and much evidence suggests that it may be a risk factor of hepatocellular carcinoma development. However several aspects of this occult infection remain unclear such as its prevalence and the factor(s) involved in the lack of circulating hepatitis B surface antigen. Moreover, it is uncertain whether the occult hepatitis B virus infection may contribute to chronic liver damage, considering that it is usually associated…

MaleACUTE VIRAL-HEPATITISPOSTTRANSFUSION HEPATITISHBV SURFACE-ANTIGENComorbidityHBV genome HBsAg-negative liver DNA liver diseasemedicine.disease_causeSeverity of Illness IndexSEROLOGICAL MARKERS; TRANSPLANT RECIPIENTS; POSTTRANSFUSION HEPATITIS; HEPATITIS C VIRUS; HEPATOCELLULAR-CARCINOMA; HBV SURFACE-ANTIGEN; ACUTE VIRAL-HEPATITIS; CHRONIC LIVER-DISEASE; POLYMERASE CHAIN-REACTION; occult hepatitis B virus infectionLiver diseaseCHRONIC LIVER-DISEASEHEPATOCELLULAR-CARCINOMAChronic/diagnosis* Hepatitis BDifferential Disease Progression Female Hepatitis B Surface Antigens/analysis* Hepatitis Bhbsag-negative; hbv genome; liver disease; liver dnaIncidenceHepatocellular/diagnosis CarcinomaLiver NeoplasmsGastroenterologyHepatitis CHepatitis BPOLYMERASE CHAIN-REACTIONPrognosisChronic/epidemiology* Humans Incidence Liver Neoplasms/diagnosis Liver Neoplasms/epidemiology* Male Prognosis Risk Assessment Severity of Illness IndexCarcinoma Hepatocellular/diagnosis Carcinoma Hepatocellular/epidemiology* Comorbidity DNA Viral/analysis Diagnosis Differential Disease Progression Female Hepatitis B Surface Antigens/analysis* Hepatitis B Chronic/diagnosis* Hepatitis B Chronic/epidemiology* Humans Incidence Liver Neoplasms/diagnosis Liver Neoplasms/epidemiology* Male Prognosis Risk Assessment Severity of Illness IndexHepatocellular carcinomaDisease Progressionhbv genomeFemaleliver diseaseCarcinoma HepatocellularTRANSPLANT RECIPIENTSRisk AssessmentDiagnosis Differentialoccult hepatitis B virus infectionHepatitis B ChronicViral/analysis DiagnosismedicineHumansRisk factorHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryCarcinomaHEPATITIS C VIRUShbsag-negativeliver dnamedicine.diseaseOccultVirologyHepatocellular/epidemiology* Comorbidity DNASEROLOGICAL MARKERSViral replicationImmunologyDNA Viralbusiness
researchProduct